Afriag Global logo

AFRI - Afriag Global News Story

6p 0.0  0.0%

Last Trade - 06/08/20

Micro Cap
Market Cap £1.90m
Enterprise Value £667k
Revenue £n/a
Position in Universe 1759th / 1818

AfriAg Global Plc: Apollon’s Dr Barnhill – Keynote Speaker Cannabiz

Tue 28th May, 2019 8:22am
28 May 2019

AfriAg Global PLC

(‘AfriAg’ or the ‘Company’)

Apollon’s Dr Stephen Barnhill – Keynote Speaker at Jamaica Cannabiz

AfriAg Global PLC, a company whose shares are admitted to trading on
London’s NEX Exchange, is pleased to announce that Dr Stephen Barnhill was a
keynote speaker on the weekend at the Second Jamiaca Cannabiz Conference at
the Faculty of Law, University of the West Indies, in Kingston Jamaica.

Dr Barnill is the key person behind Apollon Formularies Ltd (“Apollon”),
in which the Company announced a significant investment multi-staged
transaction on 16 May 2019.

About Dr. Stephen Barnhill (Proposed Chairman and Managing Director of the
Company, subject to the Right of First Refusal being exercised as announced on
16 May 2019)

Dr. Stephen D. Barnhill is a physician, Fellowship trained in Laboratory
Medicine and Board Certified by the American Board of Bioanalysis. Dr.
Barnhill is currently Chairman and CEO of Doc’s Place International, Inc.,
the first Global Centre of Excellence for Medical Cannabis Therapy in Negril,
Jamaica, as well as, Chairman and CEO Apollon Formularies, Inc., a U.S.
affiliate of Apollon Formularies Jamaica, Limited to which he also serves as
President and Board Member.

Dr. Barnhill has been a founder, Chairman and CEO of both private and public
companies. He was most recently founder, Chairman and CEO of a U.S. publicly
traded international biotech company, which he took from inception to
profitability. In addition, he was founder, Chairman and CEO of BCL
laboratories, LLC with operations in south-eastern U.S. which was acquired by
Corning–MetPath, now Quest Diagnostics, the largest clinical laboratory in
the world. Dr. Barnhill served as a Medical Director for Quest Diagnostics for
approximately 5 years after the acquisition. Dr. Barnhill was also founder,
Chairman and CEO of National Medical Specialty Labs, which was acquired by
Horus Therapeutics Inc., a New York based pharmaceutical company. Dr. Barnhill
served as President of Horus Therapeutics for several years after the
acquisition. Dr. Barnhill is a pioneer in artificial intelligence machine
learning (pattern recognition algorithms) and an inventor on more than 40
patents including neural networks and support vector machines (“SVM”)
including the Hallmark SVM-RFE technique now cited by more than 10,000
publications. His patents were part of the intellectual property portfolio
that won 1(st) Place out of 1600 publicly traded companies and was awarded the
MICO award from MDB Capital for the most disruptive intellectual property
portfolio. Dr. Barnhill’s neural network patents were acquired by Johnson &
Johnson. He is also an inventor on patents related to laboratory developed
tests and tumour markers. His work includes expertise in the clinical
laboratory involving clinical chemistry, haematology, microbiology, blood
banking, toxicology and immunology, as well as diagnostic test development
relating to cancers of the prostate, pancreas, breast and ovary, cytogenetics,
flow cytometry, FISH and imaging in digital mammography, and funduscopic
analysis of macular degeneration (AMD). He was part of the team that launched
the first iPhone app using SVM for melanoma detection. Dr. Barnhill has
negotiated and executed deals with many companies, including Pfizer,
Corning-Metpath, Quest Diagnostics, Clarient (now GE Healthcare), LabCorp,
NeoGenomics, Abbot, Bruker and others. He has published many peer reviewed
papers with academics including those from MD Anderson Cancer Centre, Johns
Hopkins University Medical Centre, Stanford University Medical Centre and
others. He is a frequently invited speaker to medical conferences in the US
and internationally. He has raised millions of dollars in start-up and ongoing
financing for both private and public companies.

Dr. Barnhill is or has been a Member or Fellow of the American College of
Physician Inventors, the American College of International Physicians, the
American Medical Association, the American College of Physician Executives,
the American Association of Artificial Intelligence, the American College of
Managed Care Medicine, the Association of Clinical Scientists, the American
Society of Contemporary Medicine and Surgery, the American Society of Law,
Medicine and Ethics, the Southern Medical Society, the American Federation for
Clinical Research, the National Federation of Catholic Physicians and the
Society of Cannabis Clinicians.

Notice Regarding Forward-Looking Statements

This announcement includes "forward-looking statements" involving the Company,
the other entities referenced in this announcement, and the respective
subsidiaries, affiliates and associates of the Company and such other entities
(collective, the “Involved Entities”), which include all statements other
than statements of historical facts, including, without limitation, those
regarding the financial position, business strategy, plans and objectives of
management for future operations, and any statements preceded by, followed by
or that include forward-looking terminology such as the words "targets",
"believes", "estimates", "expects", "aims", "intends", "will", "can", "may",
"anticipates", "would", "should", "could" or similar expressions or the
negative thereof. Such forward-looking statements involve known and unknown
risks, uncertainties and other important factors beyond the control of the
Involved Entities that could cause the actual results, performance or
achievements of the Involved Entities to be materially different from future
results, performance or achievements expressed or implied by such
forward-looking statements. Such forward-looking statements are based on
numerous assumptions regarding the present and future business strategies of
the Involved Entities and the environment in which the Involved Entities will
operate in the future. These forward-looking statements speak only as of the
date of this announcement. The Company, on behalf of itself and each of the
Involved Entities, expressly disclaims any obligation or undertaking to
disseminate any updates or revisions to any forward-looking statements
contained in this announcement to reflect any change in expectations of any
Involved Entities with regard thereto or any change in events, conditions or
circumstances on which any such statements are based. As a result of these
factors, readers are cautioned not to rely on any forward-looking statement.

The directors of the Company accept responsibility for the contents of this


For further information on AfriAg Global please visit the
or please contact;

AfriAg Global

David Lenigas (Executive
+44 (0)20 7440 0640

Peterhouse Capital
                         +44 (0)20 7469 0930

Guy Miller/Fungai Ndoro

Copyright (c) 2019 PR Newswire Association,LLC. All Rights Reserved
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.